WAT · Waters Corp · Investor Relations
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-11-10 |
Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma
BD OneFlow™ LST and BD OneFlow™ B-CLPD T1 Tests now FDA 510(k)-cleared in U.S. for identifying B-cell non-Hodgkin lymphoma (NHL) Delivers 96.3% sensitivity and 98.2% specificity 1 in identifying chronic lymphocytic leukemia (CLL), one of the most common types of NHL All-in-one solution reduces 95% of manual steps, 2 delivering workflow efficiency, fast turnaround times, and a reduction in errors MILFORD, Mass. , Nov. 10, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides pathologists and clinicians a standardized, ready-to-use flow cytometry testing solution that aids in identification and diagnosis of B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL), for faster and reliable diagnostic insights. 2 The latest in a series of innovations delivered since Waters combined with BD's Biosciences & Diagnostic Solutions Businesses, the BD OneFlow Solution integrates reagents, instruments, defined staining protocols, pre-defined assay templates, and supporting consumables into a consistent, recurring workflow for immunophenotyping normal and abnormal cell populations. The solution significantly reduces hands-on time compared to liquid reagent cocktails, helping labs increase workflow efficiency, speed turnaround time, and lower the risk of human error. "Clinical flow cytometry in the U.S. has traditionally been laboratory-developed and institution-specific," said Alexandra Kovach, M.D., Hematopathologist, Boston Children's Hospital. "Standardization of gating, analysis, and interpretation of flow cytometry data across sample types and diseases provide reproducibility, reliability, and confidence in the results for patients and their providers in our increasingly fragmented health care system. For these reasons, flow cytometry-based IVD diagnostics are well positioned to bring significant value to patient care." In 2026, an estimated 79,320 people in the U.S. will be diagnosed with NHL, including 22,760 cases of CLL, which is expected to cause approximately 4,350 deaths. 3 CLL is the most common form of leukemia in adults, accounting for approximately one-third of new leukemia cases in the U.S. 3 Expanding access to accurate, standardized diagnostic testing can help pathologists and clinicians identify disease and determine the appropriate path for further evaluation, monitoring, and treatment. "Marking the first FDA clearance from the broader BD OneFlow portfolio, the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test represent an important step toward making reliable, high-quality flow cytometry diagnostics for blood cancers more accessible to U.S. laboratories and the patients they serve," said Steve Conly, Senior Vice President, Waters Biosciences, Waters Corporation. "We want to reduce the complexity and variability that labs face in diagnosing disease, and this clearance establishes a foundation for bringing additional standardized tests to other blood cancers in the future." The broader BD OneFlow portfolio is comprised of tests built on the research and validation work of the EuroFlow™ Consortium, a collaborative research effort to develop fast, highly sensitive flow cytometry tests for diagnosis, classification, and monitoring of hematological malignancies. Within this portfolio, tests supporting the evaluation of other blood cancers including multiple myeloma (MM), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML) have been available as CE-IVD reagents. The BD OneFlow LST and BD OneFlow B-CLPD T1 Tests are available for preorder and will be commercially available in the U.S. in spring 2027 through online ordering and local representatives. For more information, please visit www.bdbiosciences.com/oneflow-us . BD is a trademark of Becton, Dickinson and Company. Waters is a |
| 2026-11-03 |
Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
Company to Provide Starting 2027 Growth Framework on Earnings Conference Call Third Quarter 2026 Highlights Total reported revenue of $1.767 billion exceeded guidance midpoint by $14 million, led by organic revenue growth of 9% as reported and 10% in constant currency, with acquired business revenue landing slightly ahead of guidance. GAAP EPS of $0.82; Adjusted EPS of $4.10 grew 21% and exceeded guidance. Analytical Sciences Division (ASD) grew 8% as reported and 9% in constant currency, led by double-digit instrument and chemistry growth from strong execution, new product innovation, and rising customer testing volume. In the Biosciences Division (WBD), reagents grew high single-digits on a prior year comparable basis, reflecting a 400bps acceleration in year-over-year growth, as research and clinical reagents both grew high single-digits; In the Advanced Diagnostics Division (ADx), microbiology grew mid-single-digits on a prior year comparable basis. The Company is raising every component of its full-year 2026 guidance, including a $43 million increase to total reported revenue at the midpoint, as new growth vectors layer onto a strong foundation of existing demand. MILFORD, Mass. , Nov. 3, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the third quarter of 2026. Overall Financial Results The Company's reported revenue for the third quarter of 2026 was $1.767 billion, reflecting $871 million of organic revenue and $896 million of revenue from the acquired Biosciences and Diagnostic Solutions businesses. Organic revenue for the third quarter of 2026 was $871 million, compared to $800 million for the third quarter of 2025, representing an increase of 9% as reported and 10% in constant currency. Revenue from Biosciences and Diagnostic Solutions was $896 million for the third quarter of 2026, compared to $885 million on a prior year comparable basis. On a GAAP basis, the Company reported a diluted earnings per share of $0.82 for the third quarter of 2026, compared to diluted EPS of $2.50 for the third quarter of 2025, reflecting acquisition-related purchase accounting charges, acquisition-related costs, and restructuring costs. Adjusted EPS for the third quarter of 2026 grew 21% to $4.10, compared to $3.40 for the third quarter of 2025. "Our team delivered exceptional results led by best-in-class consumables growth across both our Analytical Sciences and Biosciences divisions, as strong execution, new product innovation, and rising customer testing volume accelerated growth," said Dr. Udit Batra, President & Chief Executive Officer, Waters Corporation. "LC-MS instrument growth also strengthened, growing double-digits in constant currency, driven by robust instrument replacement trends, idiosyncratic growth drivers across GLP-1s, PFAS and India generics, and we continued to outperform the market with our leading solutions for complex biologics." Dr. Batra continued, "Thanks to the hard work of our teams, we are delivering ahead of schedule on our synergy and integration commitments for our acquired businesses. With improving end market conditions and momentum accelerating across the combined company, we are raising our full year 2026 revenue guidance by $43 million at the midpoint and our fourth quarter guidance calls for double digit growth in both our organic and acquired businesses on a days adjusted basis." Analytical Sciences Division (ASD) The Analytical Sciences Division – the former Waters Division, excluding the Clinical Business Unit – delivered reported revenue of $703 million in the quarter, compared to $649 million for the third quarter of 2025. Biosciences Division (WBD) The Biosciences Division – formerly known as BD Biosciences – delivered reported revenue of $396 million in the quarter, compared to $387 million for the prior year comparable period. Advanced Diagnostics Division (ADx) The Advanced Diagnostics Division comprises the former BD Diagnostic Solutions busi |
| 2026-11-03 |
Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery
Adds MOBILion's breakthrough SLIM high-resolution ion mobility technology, which separates molecules by size, shape and charge in milliseconds, complementing Waters' industry leading mass spectrometry platform, transforming samples to insights. Accelerates Waters' move into proteomics with research capabilities built for AI foundation and frontier models, pairing the unique speed and resolution of the Xevo™ MRT MS with data generation at the scale needed to power proteomics lab-in-the-loop research via Anthropic MCP and MHS protocol support. Furthers Waters' ability to take proteomics downstream to clinical applications, creating long-term opportunity to translate protein biomarker discoveries into clinical validation, as well as large-scale, blood-based screening such as for MCED and MRD monitoring. MILFORD, Mass. , Nov. 3, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced that it has acquired MOBILion Systems, Inc., the pioneer of SLIM high-resolution ion mobility separation technology for complex molecular analysis. The acquisition broadens Waters' entry into the proteomics market, pairing SLIM's separation power with Waters' Xevo™ MRT MS speed and resolution enabling superior bottom-up analysis of complex proteomes versus LC-MS alone. "Today's acquisition gives Waters a unique advantage in proteomics that will define our leadership, first in research and, over time, in the clinic. MOBILion's team brings deep expertise in developing and advancing this technology," said Dr. Udit Batra, President and Chief Executive Officer, Waters Corporation. "Pairing SLIM ion mobility separation with the speed, resolution and sensitivity capabilities of our mass spectrometry portfolio will help scientists better understand complex biology and transform data into actionable insights. It will also enable data generation at the scale AI foundation and frontier models need, opening the door to revolutionizing proteomics with lab-in-the-loop workflows." Strategic Benefits of the Acquisition This acquisition accelerates Waters' strategy to enter and drive innovation in the attractive proteomics market, where LCMS proteomics is a $2 billion Total Addressable Market (TAM), growing at a high single-digit rate. 1 It creates several benefits: Greater proteome depth through enhanced separation : MOBILion's SLIM (Structures for Lossless Ion Manipulations) technology provides high-resolution ion mobility separation, resolving molecular differences that are difficult to distinguish by liquid chromatography and mass spectrometry alone. Combined with Waters' mass spectroscopy portfolio, SLIM technology is expected to increase proteome coverage, sensitivity and throughput for complex biological samples. Waters' high-end proteomics instruments will drive insights enabling downstream translational studies. High-throughput proteomics for AI-enabled research : SLIM enabled technology will drive insights supporting large cohort studies and high-throughput generation of high-quality data required by foundation and frontier AI models. Through Waters AI Link, which brings Anthropic's Model Context Protocol (MCP) to waters_connect™ Software, and Waters' participation in Anthropic's Model Hardware Standard (MHS) research program, these capabilities support lab-in-the-loop experimentation, in which AI agents help design experiments and autonomously direct instrument operation. The acquisition also brings MOBILion's team and deep ion mobility expertise to Waters. Future translation of discoveries into targeted assays : Using the Xevo TQ Absolute XR tandem quadrupole Mass Spectrometer, which offers industry-leading sensitivity and robustness, the acquisition creates a path from biomarker discovery to targeted biomarker verification and validation in clinical trial cohorts on a single platform as workflows in the waters_connect Platform support method transfer from discovery into development. Longer-term o |
| 2026-10-28 |
Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
Advances Waters' strategy to bring trusted AI, ML, and automation capabilities to the 500,000 Empower™ Software users who run the world's regulated chromatography labs and support the release of over 80% of medicines globally AI-Powered Peak Integration transforms chromatography data processing in regulated environments, using AI to reduce manual interventions by up to 95% while delivering 76% greater accuracy and a 72% reduction in user-to-user variability Joins a growing portfolio of premium AI capabilities Waters is building directly into Empower Software, uniquely enabling AI, ML, and automation inside the validated environment where highly protected customer data resides, with no compromise to integrity, traceability, or compliance MILFORD, Mass. , Oct. 28, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced AI-Powered Peak Integration, the next step in its strategy to build intelligent AI, machine learning, and automation cloud-based capabilities directly into Empower Software, the chromatography data system of record for regulated laboratories worldwide. "Waters is using AI to help customers bring drugs to market faster and to increase the quality testing of manufactured molecules," said Tina Wu, Senior Vice President, Waters Analytical Sciences, Waters Corporation. "Our Empower Software has been the system of record for regulated chromatography for decades, holding terabytes of validated data for each customer, inside their own workflows, and under their own control. The potential behind compliant data at scale is one that no other platform can offer as we enable customers to realize the benefits of AI within their regulated workflows." Wu continued, "Our customers want the greater speed, accuracy, and productivity that AI brings, without giving up control of their data or the compliant audit trail behind it. That is why it is a central pillar of how we are advancing Empower Software as AI transforms the laboratory. Every one of these premium subscription-based capabilities reaches our large and growing installed base, so each release makes Empower Software more valuable to the laboratories already running it. We have a full pipeline of capabilities ahead as we deliver on our strategy to advance Empower Software into the connected, intelligent platform on which regulated science runs." Enabling Unique AI Capabilities Customers Can Use Beyond Research in a Deliberate Strategy Developed in Deep Partnership with Pharma Waters is collaborating with several large pharmaceutical customers and academic institutions to create autonomous, AI-enabled research, development and QA/QC capabilities that follow the molecule, from discovery to release. This builds on two abilities unique to Waters: 1) supporting research workflows and then subsequently moving them directly into compliant settings on a single platform, and 2) enabling AI inside that compliant environment, so customers realize the benefits of AI without giving up control of their data or the compliant audit trail behind it. The same approach is advancing in biologics, where Waters is applying AI, automation, and analytical instrumentation to bioanalytical characterization, bringing large molecule workflows more closely toward the compliant foundation customers already expect for small molecules. Turning Decades of Compliant Data into an AI Advantage for Customers Designed for high-throughput, compliant applications, where consistency and audit traceability are key, Waters Empower AI capabilities drive significant efficiency and productivity gains by reducing manual effort and variability in pharmaceutical late-stage development and manufacturing QC applications, while improving accuracy of results. Because the capabilities are being built directly into Empower Software, they operate inside the validated environment where highly protected customer data already resides, bringing AI and ML directly to the data, with no compromise to integrity, traceability, |
| 2026-10-23 |
Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center, and at-home settings Through a network serving more than 850,000 physicians and healthcare providers and more than 2,200 patient service centers, Labcorp is helping expand access to cervical cancer screening nationwide First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping MILFORD, Mass. and BURLINGTON, N.C. , Oct. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026. Cervical cancer is largely preventable through routine screening and early detection of human papillomavirus (HPV), yet millions of women remain overdue for recommended tests. This collaboration is designed to help address persistent cervical cancer screening gaps by bringing more accessible screening options to patients across the United States. Labcorp will provide these HPV testing options to support its clinician programs, Gaps in Care health plan programs, and Labcorp OnDemand consumer channel. 2-8 "Barriers such as privacy, access, and socioeconomic factors can make it difficult to stay current with cervical cancer screening," said Jeff Andrews, M.D., FRCSC, Vice President of Medical Affairs, Waters Advanced Diagnostics, Waters Corporation. 5-7 "We are at the start of a new era in which screening can extend beyond the clinic, enable more personalized risk assessment, and reach people who have historically been underserved. By offering greater flexibility in how and where people are screened, our collaboration marks a critical step forward in bridging one of today's most profound care gaps." The Most Comprehensive FDA-Approved HPV Testing Option The BD Onclarity HPV Assay is the only FDA-approved HPV test that supports all American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines. 2,9 "Cervical cancer screening saves lives, but too many women still face barriers to getting screened," said Dr. Brian Caveney, Chief Medical and Scientific Officer, Labcorp. "By expanding access and options for comprehensive FDA-approved HPV testing, we can help more women stay current with recommended screening, reach those who may be overdue for care, and support earlier identification of cervical cancer risk." Certain HPV genotypes, including types 16, 18 and 45, are associated with an increased risk of cervical cancer, making genotype-specific information important for patient management. 9 As HPV vaccination has reduced infections from HPV types 16 and 18, other high-risk HPV strains now account for a growing share of cervical disease, particularly among younger, vaccinated populations. 10 The BD Onclarity HPV Assay offers extended genotyping that individually identifies HPV types 16, 18, 31, 45, 51 and 52 along with three sets of strategically pooled results, regardless of collection method, making it the most comprehensive HPV screening tool available in the U.S. today. 2,11 Waters and Labcorp intend to offer the BD Onclarity HPV Assay by the end of 2026. To learn more, visit https://womenshealth.labcorp.com/providers/cervical-cancer-screening . About Labcorp: Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities |
| 2026-10-20 |
Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option
Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027 First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping Quest Diagnostics serves half of U.S. physicians and hospitals and one in three American adults each year MILFORD, Mass. and SECAUCUS, N.J. , Oct. 20, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a collaboration intended to broaden access to clinically appropriate at-home cervical cancer screening through the FDA-cleared Onclarity™ Self-Collection Kit. 1,2,13 This collaboration is the first formed by Waters that will provide access to the Onclarity Self-Collection Kit through clinical, health plan, and consumer health channels, along with patient service centers, in the United States. Quest serves one in three American adults and one in two physicians and hospitals each year, and has a nationwide network of over 2,000 patient service centers. This marks a significant step forward in the fight against cervical cancer, positioning both companies at the forefront of closing the U.S. screening gap. Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of cervical cancer, yet screening gaps persist, in part because of the sample collection process of traditional tests, which is often inaccessible and uncomfortable for patients. 2-6 The Onclarity Self-Collection Kit used with the BD Onclarity™ HPV Assay delivers breakthrough innovation by offering at-home patient self-collection while simultaneously reporting an extended number of individual HPV genotypes to provide more comprehensive results. 7,14 "In the U.S., there are over 24 million un- and under-screened individuals and approximately 14,000 new cases of cervical cancer each year," 8 said Jeff Andrews, M.D., FRCSC, Vice President of Medical Affairs, Waters Advanced Diagnostics, Waters Corporation. "By bringing together Waters' diagnostic innovation with Quest's national reach and capabilities, we have an opportunity to make a meaningful impact for these millions of individuals who remain at risk, advancing our shared goal of eliminating this highly preventable disease." Beginning in 2027, Quest will drive expanded patient access to Waters' innovation through their broad clinician channel, their Gaps in Care channel serving health insurance plans, and their consumer-initiated testing channel, questhealth.com , all combined with access to their patient service center network. "Many women struggle to participate in traditional cervical cancer screening methods, primarily due to geographic, socioeconomic, and logistical barriers," said board-certified OB/GYN Damian ("Pat") Alagia, M.D., Senior Medical Director, Women's & Reproductive Health, Quest Diagnostics. "We believe in making healthcare more proactive, personal, and connected for all patients, including through transformational options like at-home self-collection to help fill critical gaps in access to care." With the new self-collection option, more patients will be able to collect their own sample in the comfort of their home using the Onclarity Self-Collection Kit, enabled by the BD Onclarity HPV Assay. 7 Patients will then mail the sample back to Quest or drop it off at one of the approximately 2,000 Quest patient service centers nationwide. Quest's full-service laboratory will process samples, powered by the fully automated BD COR™ System, which uses advanced robotics to prepare, analyze, and report results while preserving specimen integrity and ensuring reliable, high-quality outcomes. 9 Certain HPV genotypes, including types 16, 18, and 45, are associated with an incre |
| 2026-10-13 |
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Accelerates research and development by enabling AI-augmented workflows and automated lab-in-the-loop cycles, already a new and fast-growing source of demand for Waters' instruments and consumables Leverages Waters' unique ability to take an AI-directed experiment from the research bench into development and into Empower™ Software, carrying its audit trail as the molecule moves into downstream, regulated settings Joins Anthropic's Model Hardware Standard (MHS) research program designed to enable AI agents to operate Waters instrument hardware directly and autonomously, cutting instrument integration from weeks to hours Brings Anthropic's Model Context Protocol (MCP) to waters_connect™ Software, enabling scientists to direct Waters instruments through proprietary agents linked to large language models (LLMs), as well as Claude Science MILFORD, Mass. , Oct. 13, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that it has launched Waters AI Link, a software capability that brings Anthropic's Model Context Protocol (MCP) to its informatics platform and has joined Anthropic's Model Hardware Standard (MHS) research program. "AI can generate hypotheses faster than any lab can test them, so the bottleneck has moved from computation to the bench," said Dave Leitham, Vice President, Informatics, Waters Corporation. "Every hypothesis an AI model generates becomes a physical sample that has to be separated and measured, multiplying the sample volume running through our instruments and columns." Leitham continued, "Waters has spent years building the compliant data foundation that regulated laboratories depend on. Our strategy is simple. In research, we connect AI agents to both the data and the instruments that generate it, so scientists can move at the speed of AI. That work carries forward on the same platform through development, then into Empower Software, the compliant system of record, as a molecule reaches quality control. No other company can support an AI-directed experiment from the research bench through to validated release, for small molecules and biologics alike, in a single continuous workflow. That is Waters' advantage, and it is why we are becoming a leader in the AI transformation of the laboratory." Together, Waters AI Link and MHS will enable scientists to direct Waters instruments and connected automation through Claude, including Claude Science, Anthropic's AI workbench for scientific research, and allow AI agents to operate Waters analytical instrumentation directly and autonomously. Waters continues to deliver new AI capabilities across its informatics portfolio as laboratories move toward AI-directed and increasingly autonomous operation, an area that is already generating new demand for Waters instruments and consumables. Connecting AI Workflows Across the Laboratory, From Research to Release waters_connect Software is Waters' cloud-enabled informatics platform for instrument control, data acquisition, and scientific workflows for liquid chromatography and mass spectrometry (LC-MS). The platform serves research and development laboratories, and that work transitions into Empower Software as it advances into regulated environments. For customers in research settings, these capabilities will enable the seamless transfer of workflows between dry labs and wet labs, allowing customers to accelerate outcomes via AI-augmented workflows or via fully automated lab-in-the-loop cycles. This includes autonomous physical testing of AI-generated hypotheses, followed by measurement capture that feeds directly back to the model, which hones its predictions and designs the next experiment. Because this work runs on waters_connect Software, those same workflows can then move seamlessly into development as the molecule advances. For customers in development settings, these capabilities can enable workflow optimization and efficiency gains, unlocking AI-enhanced method development, characterization, and testing wi |
| 2026-10-01 |
Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
MILFORD, Mass. , Oct. 1, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q3 2026 financial results conference call on Tuesday, November 3, 2026, at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters' Investor Relations website at https://ir.waters.com . A replay of the webcast will also be available until at least December 1, 2026, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~15,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. Caspar Tudor, Head of Investor Relations investor_relations@waters.com View original content: https://www.prnewswire.com/news-releases/waters-corporation-schedules-third-quarter-2026-earnings-conference-call-302894900.html SOURCE Waters Corporation |
| 2026-09-28 |
沃特世重磅推出BD FACSDiscover A7光谱流式分析仪,树立标准化光谱流式细胞分析新标杆
新闻摘要: BD SpectralFX™技术可支持超过50个参数的常规实验,从而加速在对抗癌症和其他疾病研究方面的突破性发现。 依托开创性的FACSTruQ™技术,可大幅减少不同仪器和用户之间的差异,实现行业前沿的标准化水平,显著提高结果可靠性。 集成化自动进样器和BD FACSChorus™软件可帮助新老用户缩短获得研究洞察的时间。 美国马萨诸塞州米尔福德, 2026 年 9 月 14 日 /美通社/ — 沃特世公司(纽约证券交易所代码: WAT )今日宣布在全球范围内正式推出商业化 BD FACSDiscover™ A7光谱流式分析仪 ,这款仪器凭借创新技术实现了出众的光谱分辨率和灵敏度,同时还具备业内前沿的标准化水平和易用性,便于学术界、制药领域以及合同研究组织(CRO)实验室的研究人员更轻松地驾驭先进流式细胞术的强大功能。 这款全新的光谱流式分析仪进一步丰富了沃特世FACSDiscover流式细胞仪平台的产品阵容,它采用与旗舰产品BD FACSDiscover A8光谱流式分析仪相同的BD SpectralFX前沿光谱技术,支持多达5个激光器和78个荧光检测器,大幅增加了配色组合。这一技术使科学家能够分析单个细胞50个以上的特征,并获得始终一致的高质量数据。 FACSTruQ技术作为一项备受瞩目的产品创新,通过自动化设置和质量控制,实现了新一代仪器校准。流式细胞分析仪集成该技术后,能够在不同仪器、用户和实验室之间提供一致的数据,获得高度可重现的结果,即使采用超过50种染料的配色组合 [i] ,变异系数仍低于10%。结合BD FACSChorus软件的引导式工作流程和集成化自动进样器,FACSDiscover A7光谱流式分析仪为流式细胞术的实验标准化树立了新标准。 拉霍亚免疫学研究所流式细胞术核心平台高级主任Cheryl Kim表示:“FACSDiscover A7光谱流式分析仪降低了先进光谱流式细胞术的使用门槛,将为免疫学研究带来全新可能,让我们的核心平台能够以更高的标准化水平和结果可信度,帮助科学家揭示更深入的生物学洞见。非常期待FACSDiscover A7光谱流式分析仪成为我们核心平台的利器,助力研究人员充分利用光谱数据,通过开发免疫系统疾病的治疗方法和治愈方案,推进我们改善人类健康的重要使命。” 沃特世公司生物科学事业部高级副总裁Steve |
| 2026-09-14 |
Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Enables routine 50+ parameter experiments with BD SpectralFX™ Technology, accelerating breakthrough discoveries in the fight against cancer and other diseases. Minimizes instrument and user differences with first-of-its-kind FACSTruQ™ Technology, achieving industry-leading standardization for greater confidence in results. Integrated autoloader and BD FACSChorus™ Software speeds time to insight for new and experienced users. MILFORD, Mass. , Sept. 14, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today announced the global commercial launch of the BD FACSDiscover™ A7 Cell Analyzer, which uniquely combines exceptional spectral resolution and sensitivity with industry-leading standardization and ease-of-use features, making the power of advanced flow cytometry more accessible to researchers in academia and pharmaceutical settings, as well as in contract research organization (CRO) labs. The new cell analyzer expands Waters' category-defining FACSDiscover platform of flow cytometers, incorporating the same cutting-edge BD SpectralFX Technology present in the flagship BD FACSDiscover A8 Cell Analyzer, which supports up to five lasers and 78 fluorescence detectors to maximize the palette of colors. This technology enables scientists to analyze more than 50 characteristics of a single cell with consistent, high-quality data. Together with FACSTruQ Technology, a notable product innovation that delivers next-generation instrument calibration with automated setup and quality control, the cell analyzer provides data consistency across instruments, users, and sites, achieving highly reproducible results with a less than 10% coefficient of variation across a palette of more than 50 dyes. 1 Paired with the BD FACSChorus Software's guided workflows and the integrated autoloader, the FACSDiscover A7 Cell Analyzer sets a new standard for experimental standardization in flow cytometry. "The FACSDiscover A7 Cell Analyzer lowers the barrier to advanced spectral flow cytometry and will open up new possibilities for immunology research, enabling our core facility to help scientists uncover deeper biological insights with greater standardization and confidence," said Cheryl Kim, Senior Director, Flow Cytometry Core, La Jolla Institute for Immunology. "We look forward to the FACSDiscover A7 Cell Analyzer being an integral instrument for our core, allowing our researchers to get the most out of spectral data to advance our important work of improving human health through the development of treatments and cures for immune system disorders." Steve Conly, Senior Vice President, Waters Biosciences, Waters Corporation, added, "The FACSDiscover A7 Cell Analyzer couples advanced spectral performance and leading standardization with a compelling price-to-performance balance, bringing spectral flow cytometry within reach of more researchers than ever before, for applications from biomarker discovery to drug development. Just two years after the world's very first 50-color flow cytometry panel was developed on the BD FACSDiscover™ S8 Cell Sorter, 2 the FACSDiscover A7 Cell Analyzer extends these transformative capabilities, helping labs meet their increasingly critical needs for reproducibility within our connected ecosystem of instruments, reagents, and informatics." The FACSDiscover A7 Cell Analyzer is now commercially available globally and available to order through local representatives. For more information, please visit waters.com and bdbiosciences.com/A7 . BD is a trademark of Becton, Dickinson and Company. Waters is a trademark of Waters Corporation or its affiliates. All other marks are the property of their respective owners. About Waters Corporation: Waters Corporation (NYSE: WAT ) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harne |
| 2026-09-11 |
Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference
MILFORD, Mass. , Sept. 11, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on Wednesday, September 23, 2026, at 12:00 PM BST (GMT+1) / 7:00 AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com . A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. Caspar Tudor, Head of Investor Relations investor_relations@waters.com View original content: https://www.prnewswire.com/news-releases/waters-corporation-to-present-at-the-jp-morgan-us-all-stars-conference-302874227.html SOURCE Waters Corporation |
| 2026-08-26 |
Waters Corporation to Present at the Wells Fargo Healthcare Conference
MILFORD, Mass. , Aug. 26, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 21 st Annual Healthcare Conference on Wednesday, September 9th, 2026, at 10:15 AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com . A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. Caspar Tudor, Head of Investor Relations investor_relations@waters.com View original content: https://www.prnewswire.com/news-releases/waters-corporation-to-present-at-the-wells-fargo-healthcare-conference-302859710.html SOURCE Waters Corporation |
| 2026-08-04 |
Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
Second Quarter 2026 Highlights Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses. Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments. Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew 4% on a prior year comparable basis, reflecting strong traction from commercial execution and operational improvements under the Company's 180-day growth revitalization plan that drove a faster-than-expected acceleration to mid-single-digit growth. GAAP EPS of ($1.39); Adjusted EPS of $3.05 landed at the high end of the guidance range, as early cost actions offset unfavorable foreign exchange translation. The Company is raising all components of its full-year 2026 guidance, given better-than-expected results and broad strengthening in end-market conditions. It now expects full-year 2026 organic constant currency revenue growth of 7% to 9%, acquired business reported revenue of $3.045 billion, and adjusted EPS of $14.45 to $14.65, reflecting 10-12% growth. MILFORD, Mass. , Aug. 4, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT),today announced its financial results for the second quarter of 2026. Overall Financial Results The Company's reported revenue for the second quarter of 2026 was $1.645 billion, reflecting $828 million of organic revenue and $817 million of revenue from the recently acquired Biosciences and Diagnostic Solutions businesses. Organic revenue for the second quarter of 2026 was $828 million, compared to $771 million for the second quarter of 2025, representing an increase of 7% as reported and 9% in constant currency. Revenue from Biosciences and Diagnostic Solutions was $817 million for the second quarter of 2026, compared to $783 million on a prior year comparable basis. On a GAAP basis, the Company reported a diluted loss per share of $1.39 for the second quarter of 2026, compared to diluted EPS of $2.47 for the second quarter of 2025, reflecting acquisition-related purchase accounting charges, including amortization of acquired intangibles and inventory step-up. Adjusted EPS for the second quarter of 2026 grew 3% to $3.05, compared to $2.95 for the second quarter of 2025. "Thanks to the hard work of our teams, we delivered industry-leading growth again this quarter, executing ahead of guidance across all four divisions," said Udit Batra, Ph.D., President & Chief Executive Officer, Waters Corporation. "Organic revenue grew 9% in constant currency, and our newly acquired businesses grew mid-single-digits in their first full quarter under Waters ownership. This performance reflects strong execution across the combined Company as our integration continues to gain momentum, while the recovery across our end markets has broadened with previously lagging customer segments now returning to growth." Dr. Batra continued, "With momentum building across our portfolio, end markets, and synergies, we are raising every component of our full-year 2026 guidance. Looking ahead, as end market conditions continue to strengthen and our growth strategy compounds, Waters is better positioned today than at any point in our recent history, with a broader portfolio, a larger installed base, and the clearest set of growth catalysts we have ever had." Analytical Sciences Division (ASD) The Analytical Sciences Division – the former Waters Division, excluding the Clinical Business Unit – delivered reported revenue of $669 million in the quarter, compared to $627 million for the second quarter of 2025. Biosciences Division (WBD) The Biosciences |
| 2026-07-27 |
Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. Offers 5x greater sensitivity vs. in-class instruments with lower detection limits in smaller sample volumes, introducing a step-change in analytical performance for complex biological matrices. Up to six-fold increase in robustness with StepWave™ XR Ion Guide vs. Xevo TQ Absolute MS, advancing laboratory productivity and performance consistency. MILFORD, Mass. , July 27, 2026 /PRNewswire/ -- The Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Meeting — Waters Corporation (NYSE: WAT) today announced the launch of the Xevo TQ Absolute XR IVD Mass Spectrometer, expanding its MassTrak™ IVD System portfolio of LC-MS/MS Systems with a solution that combines class-leading sensitivity and enhanced robustness for clinical applications. The new system builds on the industry-renowned step-change performance of the Xevo TQ Absolute IVD Mass Spectrometer, which established the benchmark for sensitivity among IVD-compliant tandem quadrupole mass spectrometers. 1 Developed for routine laboratory testing requiring IVD-compliant systems, the Xevo TQ Absolute XR IVD System delivers exceptional trace-level analytical performance in complex biological matrices. With up to five times greater sensitivity than other instruments in its class, 1 the system enables lower limits of detection and reliable quantification of challenging analytes from smaller sample volumes. This enhanced sensitivity is critical for applications requiring accurate measurement at very low concentrations, such as low-level estradiol testing for women's health and hormone-related cancer assessment, 2 and hair toxicology 3 for detecting drugs of abuse and documenting long-term exposure. "Waters' IVD Systems provide clinical diagnostic laboratories with highly precise and flexible solutions that help clinicians make informed decisions when every test matters," said Jianqing Bennett, Senior Vice President, Waters Advanced Diagnostics, Waters Corporation. "With the introduction of the Xevo TQ Absolute XR IVD System, Waters is delivering a new standard of sensitivity and robustness that can significantly reduce downtime and improve laboratory productivity. Waters is uniquely positioned to help clinical laboratories develop reliable methods for complex analytes and expand their testing capabilities to meet growing demand across women's health, cancer assessment, and toxicology applications." Featuring the new StepWave™ XR Ion Guide, the Xevo TQ Absolute XR IVD System delivers improved robustness, enabling ion ratio consistency for up to six times longer compared with the Xevo TQ Absolute IVD System. 4 This advancement gives laboratories greater confidence in consistent performance when analyzing complex clinical samples containing phospholipids, salts, and other matrix components. "Having the Xevo TQ Absolute XR IVD Systems in our laboratory is a major advancement for the company," said James Nutt, Head of Laboratory Operations, Cansford Laboratories. "The systems strengthen our analytical reliability, have the potential to greatly expand our substance testing capabilities, and improve operational efficiency. They deliver better signal stability and improved sensitivity, which is especially important when working close to decision cut-offs in complex matrices such as human hair. This gives us greater confidence in our results and provides additional assurance when measuring analytes at very low concentrations." This new MassTrak LC-MS/MS IVD System includes the ACQUITY™ UPLC I-Class PLUS System with the Xevo TQ Absolute XR IVD Mass Spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to deliver fast, accurate sample analysis that enhances mass spectrometer performance and simplifies the characterization of complex samples. Together, the integrated system delivers indu |
| 2026-07-02 |
Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
MILFORD, Mass. , July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters' Investor Relations website at https://ir.waters.com . A replay of the webcast will also be available until at least September 1, 2026, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about . Caspar Tudor, Head of Investor Relations investor_relations@waters.com View original content: https://www.prnewswire.com/news-releases/waters-corporation-schedules-second-quarter-2026-earnings-conference-call-302816469.html SOURCE Waters Corporation |
| 2026-06-24 |
IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
IMU's AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time. Waters Biosciences' technologies, including BD FACSDiscover™ and BD Rhapsody™ Instruments, will be used with IMU's AI analytics in research to deliver deeper, population-level disease insights. Partnership supports IMU's expansion of its world-leading immune dataset through large-scale studies, establishing a new standard for immune profiling. MILFORD, Mass. , June 24, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) and IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, today announced a strategic partnership to accelerate the development of IMU's next-generation AI-powered High Definition (HD) Immunology platform. The partnership brings together Waters Biosciences' advanced flow cytometry and single-cell technologies, 1 including BD FACSDiscover Cell Analyzers, BD flow cytometry reagents with BD Horizon™ Real Dyes, BD Rhapsody Instruments, and BD OMICS-One™ WTA Next Assay and Protein Panels, with IMU's HD analysis and proprietary AI and machine learning analytics, that can reproducibly characterize the immune system in real time, to turn complex immune data into insights at scale across discovery, translational, and clinical research applications. IMU measures the immune system in unprecedented detail, delivering more than 100 million data points from a single blood sample, 2 combining HD multiomic analysis with machine learning analytics. IMU is building the world's largest immune dataset, 3 with unrivaled access to patient samples and population-wide clinical data, establishing a universal standard for immune profiling. "Waters Biosciences was the clear partner to help IMU Biosciences scale our HD Immunology platform to the level required for true population-wide immune mapping, given their longstanding leadership in high-throughput flow cytometry and single-cell technologies," said John Baker, Ph.D., Chief Executive Officer, IMU Biosciences. "Our world-leading immune dataset and proprietary AI analytics will unlock the potential of Waters' best-in-class analytical instruments, accelerating our work to decode the immune system and power the next generation of precision medicine." Steve Conly, Senior Vice President, Waters Biosciences, Waters Corporation added, "By partnering with IMU Biosciences, we are helping to build the most detailed picture of the human immune system ever assembled at clinical scale. Together, our companies' cutting-edge technologies across instruments, reagents, and informatics will help advance immune profiling into a standardized, universally accessible clinical tool that can be used across the continuum of care for cancer and other diseases, supporting smarter, faster drug development." The companies intend to pursue additional studies in translational research for novel biomarker discovery to enable clinical applications in flow cytometry. Waters Biosciences and IMU Biosciences presented data at the annual meeting of the International Society for the Advancement of Cytometry (CYTO 2026), demonstrating system-level immune profiling on the BD FACSDiscover A8 Cell Analyzer with a 58-color spectral panel using BD reagents, and i |
| 2026-06-09 |
Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis
Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway. Unique whole-cell design eliminates cell teardown, reducing sample preparation time by >90%. Industry-leading Coin Cell DSC temperature range from –80 °C to 600 °C, aiding battery development and QA/QC. MILFORD, Mass. , June 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced the launch of the Waters TA Instruments™ Coin Cell Differential Scanning Calorimeter (DSC), designed to transform battery safety testing. Purpose-built for battery scientists, the Coin Cell DSC enables direct testing of fully assembled coin cells, eliminating time-intensive preparation steps while delivering faster, more descriptive safety and performance insights. The Coin Cell DSC is the only commercially available DSC 1 that provides multidimensional data capture and enables researchers to collect whole-cell thermal data while simultaneously measuring evolved gas and electrochemical performance. By incorporating voltage monitoring and charge/discharge capability, researchers can directly correlate thermal and electrochemical behavior enabling earlier insights into thermal runaway and battery failure. It can also be coupled with MS, Fourier Transform Infrared Spectroscopy (FTIR), or Gas Chromatography-Mass Spectrometry (GC-MS) to enable direct analysis of off-gas composition. "The Coin Cell DSC represents a significant advancement in battery thermal analysis," said Yu Cheng, Vice President, Research and Development and Product Solutions, Materials Sciences, Waters Corporation. "Simultaneously capturing thermal, evolved gas, and electrochemical data is not only faster, but also correlates data from the same sample for more exacting insights earlier in development. With its broad temperature range and streamlined workflows, the system is designed to reduce experimental complexity while outperforming current approaches." The Coin Cell DSC introduces a unique capsule design that eliminates the highly time-consuming need for cell teardown, reducing the average sample preparation time by more than 90%. 2 This approach preserves sample integrity while significantly accelerating data generation. The new system redefines thermal analysis by integrating advanced temperature performance, efficient workflows, and multidimensional data capture into a single platform. With an industry-leading –80 °C to 600 °C range, 3, 4 the Coin Cell DSC enables comprehensive analysis of low- and high-temperature behavior, expanding future applications in development and QA/QC. "The battery industry has long needed a solution that bridges the gap between materials thermal analysis and ful |
| 2026-06-09 |
沃特世推出集热分析、逸出气体分析和电化学分析功能于一体的Coin Cell差示扫描量热仪(DSC),助力推动电池安全研究
新闻摘要: 将热流、逸出气体和电化学分析集成于单次实验中,实现对热失控现象的早期洞察。 独特的全电池测试设计免去了拆解电池的步骤,将样品制备时间缩短了90%以上。 行业翘楚的Coin Cell DSC检测温度覆盖–80到600 ℃,有助于电池开发与质量保证/质量控制 (QA/QC)。 美国马萨诸塞州米尔福德,2026年6月9日 - 沃特世公司(纽约证券交易所代码: WAT )今天宣布推出专为变革电池安全测试而设计的WatersTM TA Instruments™ Coin Cell差示扫描量热仪(DSC)。这款仪器专为电池研发人员量身打造,可直接测试全组装纽扣电池,省去繁琐的前处理步骤,同时提供更快、更全面的安全与性能表征数据。 Waters TA Instruments Coin Cell差示扫描量热仪(DSC) Coin Cell DSC是目前市场上少有的能够实现多维数据采集的商用差示扫描量热仪 1 ,可在执行全电池热分析的同时,并行测量逸出气体与电化学性能。通过集成电压监测及充放电功能,研究人员可直接建立热行为与电化学行为之间的关联,从而更早获得关于热失控和电池失效的洞察。此外,该系统还可与质谱仪(MS)、傅里叶变换红外光谱仪(FTIR)或气相色谱-质谱系统(GC-MS)联用,直接分析逸出气体成分。 沃特世公司材料科学事业部研发与产品解决方案副总裁 Yu Cheng表示:“Coin Cell DSC是电池热分析领域的一项重大突破。并行采集热分析、逸出气体及电化学数据,不仅显著提升测试效率,更能在研发早期阶段精准关联同一样品多个维度的数据,获取更深入的见解。得益于宽泛的测试温度范围与精简的工作流程,该系统能降低实验复杂程度,在性能方面也优于现有测试方案。” Coin Cell DSC采用独特的胶囊式设计,省去了拆解电池这一耗时的操作步骤,平均样品制备时间缩短了90%以上 2 。这种设计在有效保护样品完整性的同时,大幅加快了数据获取速度。 这款全新系统兼具出众的温度性能、高效的工作流程与多维数据采集功能,重新定义了电池热分析的性能技术标准。Coin Cell DSC的测试温度范围覆盖–80至600 ℃ 3, 4 ,属业内前列水平,可全方位表征电池的低温与高温行为,拓展未来在研发和质量保证/质量控制 (QA/QC) 中的应用。 |
| 2026-06-08 |
Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
Faster run times for GLP-1 , insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks. Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory readiness. Industry-first chemical and physical particle optimization delivers reproducible methods for increasingly complex biologics. MILFORD, Mass. , June 8, 2026 /PRNewswire/ -- 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques—Waters Corporation (NYSE: WAT) today announced the launch of the BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, a first-of-its-kind reversed-phase (RP) column platform designed to tackle a persistent biopharmaceutical challenge: reliably separating structurally and chemically similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs) to support the development of safe, effective drug products. In GLP-1 receptor agonists and newer mRNA-based therapies such as in vivo CAR T, difficulty resolving impurities can delay time to market, weaken regulatory confidence, and affect patient safety. Traditional RP columns do not always separate low-level or closely related impurities well, often requiring longer analyses, detector-suppressing mobile-phase additives, or repeated method redevelopment. BioResolve Peptide and GTxResolve Lipid Columns help to overcome these limitations with ready-to-use methods that improve both resolution 1,2 and speed 2,3 while fitting into existing workflows. "We have made simultaneous advances in both chemistry and particle physics to deliver the first columns Waters has introduced to market specifically QC batch-tested for GLP‑1 analysis 4 and lipid nanoparticles, 2 solving a longstanding customer pain point," said Erin Chambers, Vice President, General Manager, Consumables & Lab Automation, Waters Analytical Sciences, Waters Corporation. "BioResolve Peptide and GTxResolve Lipid Columns are designed to resolve chemically similar GLP‑1 impurities and LNP components faster when speed matters, 2,3 and with extraordinary resolution 1 when certainty is required. The result is simpler method development, regulatory‑ready data, 5 and faster, highly reproducible methods, ultimately helping to reduce cost burdens on important new therapeutics." BioResolve Peptide and |
| 2026-06-08 |
沃特世率先推出反相生物分离色谱柱,GLP-1表征速度提升高达3倍、LNP组分分析提速2倍
新闻摘要: 缩短GLP-1、胰岛素及LNP原料药检测运行时间,加速生物制药开发进程并减少生产瓶颈。 分辨率和灵敏度提升达2倍,可识别和追踪低水平杂质,提升法规合规准备度。 业内开创性化学与物理颗粒优化技术,为日益复杂的生物制品提供可重现的方法。 美国马萨诸塞州米尔福德,2026年6月8日 - 第55届高效液相分离及相关技术国际研讨会 - 沃特世公司(纽约证券交易所代码:WAT)今日宣布推出BioResolve™肽类及GTxResolve™脂质苯己基+(Phenyl-Hexyl+)和C18+色谱柱。这一业界创新的反相(RP)色谱柱平台专为攻克生物制药领域的一项长期难题而设计:能够可靠分离GLP-1肽、胰岛素及脂质纳米颗粒(LNP)中结构与化学性质极为相似的杂质,从而支持安全、有效的药物产品开发。 在GLP-1受体激动剂及新型mRNA疗法(如体内CAR T)的研发中,杂质分离困难往往会导致上市延迟、削弱监管机构的信心,并影响患者用药安全。传统反相色谱柱在分离低含量或结构高度相似的杂质时表现欠佳,通常需要更长的分析时间、依赖抑制检测器信号的流动相添加剂,或需反复重新开发方法。BioResolve肽类与GTxResolve脂质色谱柱凭借即用型方法,成功突破了上述局限,在兼容现有工作流程的同时,实现了分辨率 1,2 与分析速度 2,3 的同步提升。 沃特世公司分析科事业部副总裁兼消耗品与实验室自动化总经理Erin Chambers表示:“我们在化学填料与颗粒物理结构方面取得了双重突破,推出了沃特世首批专门针对GLP-1分析 4 及脂质纳米颗粒 2 进行质控(QC)批量检测认证的色谱柱,解决了客户长期以来的痛点。BioResolve肽类与GTxResolve脂质色谱柱旨在以更快的速度 2,3 分离化学性质相近的GLP-1杂质与LNP组分,并在需要确证性结果时提供出色的分辨率1。这不仅简化了方法开发,提供了合规性数据5,更为客户带来快速且具有高重现性的分析方法,最终有效降低重要新疗法的成本负担。” BioResolve肽类与GTxResolve脂质色谱柱采用特殊设计的表面化学与表面多孔颗粒技术,可针对这两类难分离样品提供高度准确的反相分离选择性。该系列色谱柱可提供苯己基+与C18+两种化学填料,采用230 |
| 2026-06-03 |
Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics. Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention. Fully automated solution delivers an industry-leading 50% increase in vial loading and up to 960-vial per module capacity, maximizing walk-away time. MILFORD, Mass. , June 3, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides a new option for laboratories seeking a fully automated blood culture system designed to improve the speed, consistency, and accuracy of sepsis and bloodstream infection diagnostics in modern microbiology laboratories. Clinical study data¹ showed that the BD BACTEC FXI Culture System reduced mean time to detection by approximately three hours (~15%) compared with the previous-generation BD BACTEC™ FX Blood Culture System (17 hours vs. 20 hours). Faster detection enables earlier pathogen identification and more timely targeted antimicrobial therapy for patients with suspected bloodstream infections and sepsis. Because each hour of delayed sepsis treatment increases mortality by 3.6% to 9.9%, 2 faster diagnostic workflows are critical in acute care settings. "Recent evidence-based laboratory guidelines document the beneficial clinical impact of rapid laboratory results for the detection of bloodstream infections; therefore, advancing the science of automated blood culture instruments is critical to further speed results," said Donna M. Wolk, MHA, Ph.D., D(ABMM), Division Chief, Molecular and Microbial Diagnostics and Development, Geisinger Medical Laboratories. "Reducing the time to detection for positive results is key to improving the availability of Gram stain and other tests, on which treatment decisions are based. The faster, the better." The BD BACTEC FXI Culture System features a first-of-its-kind capability in a blood culture platform – an automated gravimetric measurement of individual blood culture vial volume. By objectively confirming blood volume in each vial, the system reduces pre-analytical variability and supports more consistent diagnostics and adherence to recommended collection practices. "Waters is proud to bring the BD BACTEC FXI Culture System to the U.S. market, delivering an important advancement in bloodstream infection diagnostics," said Jianqing Bennett, Senior Vice President, W |
| 2026-06-01 |
Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding. Sets a new benchmark for throughput in high-resolution spatial analysis with the DESI XS source, supporting higher-confidence studies of disease and treatment response. MILFORD, Mass. , June 1, 2026 /PRNewswire/ -- 74 th ASMS Conference on Mass Spectrometry and Allied Topics—Waters Corporation (NYSE: WAT) today introduced the Waters Xevo™ MRT P10 Mass Spectrometer , a high-resolution Quadrupole Time-of-Flight (QToF) System for high-throughput multiomics, bioanalysis, and biopharmaceutical laboratories. The Xevo MRT P10 MS delivers up to 20x higher MS/MS sensitivity compared to its predecessor, along with industry-leading speed and expanded acquisition modes to comprehensively support both targeted and untargeted analysis in a single benchtop platform. The system is designed to accelerate biomarker discovery and validation while supporting the identification of disease pathways and therapeutic targets across large-cohort biomedical research and epidemiology studies. "With the Xevo MRT P10 MS, we are raising the standard for benchtop high-resolution mass spectrometry," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation. "By combining enhanced MS/MS sensitivity, the industry's fastest benchtop acquisition speeds, and advanced intelligent acquisition modes in LC-MS/MS – and layering in a new benchmark for MS imaging speed and throughput with our DESI XS – this platform empowers researchers to see more biology, accelerate discovery, and make confident decisions. The Xevo MRT P10 MS represents a powerful step forward for our customers working to advance multiomics research and life‑changing therapies." As researchers pursue deeper analytical insights, they face a bottleneck: generating high quality MS/MS information at the speed required by modern workflows. The Xevo MRT P10 MS is engineered to solve that problem. It offers up to 20× gre |
| 2026-06-01 |
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals. 50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics. Integrated MALDI XS and DESI XS imaging with high-resolution ion mobility enables direct visualization of molecules in tissue, improving understanding of how disease develops at the cellular level. MILFORD, Mass. , June 1, 2026 /PRNewswire/ -- 74 th ASMS Conference on Mass Spectrometry and Allied Topics— Waters Corporation (NYSE: WAT) today announced the launch of the Waters Cyclic IMS P20 Mass Spectrometer , a high-resolution structural and spatial omics platform designed to help scientists see biology more clearly, and act on it faster. Combining multipass Cyclic Ion Mobility Spectrometry with an enhanced suite of fragmentation, probing, and imaging capabilities , this unique and powerful instrument delivers confident insights for the early detection of disease signals, from protein misfolding to post-translational modifications. The system's full‑spectrum molecular imaging unlocks unparalleled visualization within a single experiment 1 to accelerate discovery and development, and power deeper understanding of complex biology. "Waters recognizes that advanced tools for structural and spatial omics play a critical role in delivering therapeutic breakthroughs," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation. "With its powerful fusion of capabilities, the Cyclic IMS P20 MS delivers a previously unattainable view into subtle molecular differences, unlocking a new level of understanding of the mechanisms that drive disease and advancing next‑generation discovery." As researchers pursue larger and more heterogeneous therapeutic targets, analytical workflows need higher sensitivity, higher structural resolution, and easier-to-adopt methods |
| 2026-06-01 |
沃特世重磅推出Cyclic IMS P20 质谱仪,树立结构生物学与空间组学研究的新标杆
新闻摘要 : MS/MS灵敏度提升逾10倍,结合多循环环形离子淌度谱(Cyclic™ IMS),可揭示细微的生物学差异,更早甄别疾病信号,突破以往的检测局限 1 。 量范围上限扩展50%以上,结合全面的结构分析工具助力新一代生物治疗药物开发 2 。 集成MALDI XS和DESI XS成像离子源,结合高分辨率离子淌度技术,可实现组织中分子的全面可视化,有助于深入探索疾病在细胞水平的发生机制 3 。 美国马萨诸塞州米尔福德,2026年6月1日 - 第74届美国质谱年会(ASMS)- 沃特世公司(纽约证券交易所代码:WAT)今日隆重推出 Waters TM Cyclic TM IMS P20高分辨质谱仪 ,用于结构生物学和空间组学等领域的研究,旨在帮助科学家更清晰地洞察生物学本质,更高效地将发现转化为行动。该仪器将环形离子淌度质谱技术与一系列增强型碎裂、电离和成像模式深度融合,不仅设计新颖,而且功能强大,能够为疾病信号的早期检测提供可靠的科学依据,广泛适用于蛋白质错误折叠到翻译后修饰等应用场景。该系统搭载全谱分子成像功能,可通过单次实验实现出色的可视化效果,突破了以往的技术局限1,能够加速药物发现和开发进程,助力科研人员深入解析复杂生物学机制。 Waters Cyclic IMS P20 质谱仪将多循环离子淌度谱技术与增强型碎裂、电离和成像模式融合,能够揭示细微的生物学差异,获得对疾病信号更早、更精确、此前难以实现的检测。 沃特世公司分析科学事业部液相色谱-质谱副总裁兼总经理James Hallam表示:“沃特世深知,先进的结构生物学和空间组学研究工具,是推动治疗药物取得突破性成果的关键驱动力。凭借强大的多维功能融合,Cyclic IMS P20 质谱仪能够以全新视角揭示分子的细微差异,将科研人员对疾病驱动机制的认知提升至全新高度,有力推动新一代药物的发现进程。” 随着研究人员不断探索更大、异质性更高的治疗靶点,分析工作流程对灵敏度、结构分辨率和方法易用性的要求也越来越高。Cyclic IMS P20质谱仪正是为此而生:与上一代产品相比,其MS/MS灵敏度跃升逾10倍2,质量范围上限扩展50%以上,超过了100 |
| 2026-05-18 |
Waters Corporation to Present at the Jefferies Global Healthcare Conference
MILFORD, Mass. , May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3rd, 2026, at 10:30 AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com . A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in life sciences, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with analytical laboratories around the world to advance the release of effective, high-quality medicines, assure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combatting growing antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of approximately 16,000 employees partner with our customers to turn scientific challenges into breakthroughs that improve lives worldwide. Caspar Tudor, Head of Investor Relations investor_relations@waters.com View original content: https://www.prnewswire.com/news-releases/waters-corporation-to-present-at-the-jefferies-global-healthcare-conference-302775033.html SOURCE Waters Corporation |
Past events
Source: https://ir.waters.com/